This filing has no standalone trading signal. The market will focus on the Q3 2026 earnings results on October 29, particularly growth product sales (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO), progress on the ONAPGO second supplier FDA submission, and any updates on the pending Indivior merger.
Price Chart
Executive Summary
Supernus Pharmaceuticals filed an 8-K on October 19, 2026, solely to announce the date of its Q3 2026 earnings release and conference call (October 29, 2026). No financial results, guidance changes, or material business updates were included in this filing. The cross-filing context shows a prior Q2 2026 earnings release (August 3, 2026) that reported strong revenue growth, raised full-year guidance, and disclosed a pending merger of equals with Indivior Pharmaceuticals.
Key Facts
- Filing is a routine 8-K announcing the date of Q3 2026 earnings release and conference call.
- Earnings will be reported after market close on October 29, 2026.
- No financial data, guidance, or material business developments are included in this filing.
- Prior Q2 2026 earnings (August 3, 2026) showed total revenues of $219.1M (+32% YoY) and raised full-year 2026 guidance.
- The prior earnings release also disclosed a definitive agreement to merge with Indivior Pharmaceuticals in an all-stock merger of equals.
Financial Impact
No financial impact from this filing — it is a date announcement only.
Risk Factors
- No new information in this filing — risk is limited to the upcoming Q3 earnings results.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001356576-26-000043 |
| Exhibit: ex-99110x19xearningscallan.htm | 0001356576-26-000043 |
| Document: 0001356576-26-000043-index-headers.html | 0001356576-26-000043 |
| Document: 0001356576-26-000043-index.html | 0001356576-26-000043 |
| Document: 0001356576-26-000043.txt | 0001356576-26-000043 |
| 8-K Data (Synthetic) | 0001356576-26-000043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $40.77 | awaiting T+5 | awaiting T+5 | $40.96 (+0.47%) |
Oct 26, 2026 2d ago | Court Ruling | $40.66 | awaiting T+5 | awaiting T+5 | $40.96 (−0.74%) |
Oct 21, 2026 6d ago | 8-K | $42.07 | awaiting T+5 | awaiting T+5 | $40.96 (−2.64%) |
Oct 19, 2026 8d ago | 8-K | $41.23 $40.54 | ▼ −1.67% | ▼ −1.70% | $40.96 (−0.65%) |
Oct 19, 2026 8d ago | Press Release | $39.84 $40.63 | ▲ +1.98% | ▲ +2.13% | $40.96 (+2.81%) |
Oct 6, 2026 21d ago | 425 | $42.83 $42.01 | ▼ −1.91% | ▼ −1.78% | $40.96 (−4.37%) |
Oct 6, 2026 21d ago | DEFA14A | $42.83 $42.01 | ▼ −1.91% | ▼ −1.78% | $40.96 (−4.37%) |
Sep 11, 2026 6w ago | DEFM14A | $41.49 $42.78 | ▲ +3.11% | ▲ +3.00% | $40.96 (−1.28%) |
Aug 3, 2026 12w ago | DEFA14A / 425 | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $40.96 (−5.29%) |
Aug 3, 2026 12w ago | 8-K | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $40.96 (−5.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers